JPRN-UMIN000031117已完成未知
Multicenter, prospective interventional study to evaluate therapeutic effect of Afatinib in patients with advanced non-small cell lung cancer, EGFR mutation positive and brain metastasis - Afatinib MET-PET/CT study
First Department of Internal Medicine, Shinshu University0 个研究点目标入组 1 人开始时间: 2018年2月3日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
- 入组人数
- 1
研究概览
简要总结
In one enrolled case, treatment with Afatinib reduced the SUVmax and LNRmax rates of brain metastases.
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 ot applicable（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1)Idiopathic pulmonary fibrosis, interstitial pneumonia, pneumoconiosis, active radiation pneumonitis, drug pneumonia, etc. are complicated 2)Active other malignancy 3)Adjuvant chemotherapy 4)Infection to need to treat with antibiotics or antifungal agent via intravenous administration
研究者
相似试验
已完成
不适用
Afatinib MET-PET/CT Studyon-small-cell lung carcinomaJPRN-jRCTs031180271Hanaoka Masayuki1
Unknown
2 期
Apatinib Plus Radiotherapy for Patients With Brain Metastases From Non-small-cell Lung CancerBrain MetastasesNCT03356600Shanxi Province Cancer Hospital44
已完成
3 期
Lapatinib Plus Capecitabine Versus Trastuzumab Plus Capecitabine in ErbB2 (HER2) Positive Metastatic Breast CancerMetastases, BrainNCT00820222Novartis Pharmaceuticals540
终止
1 期
Cambridge Brain Mets Trial 1Brain CancerLung CancerAdvanced Lung CancerBreast CancerAdvanced Breast CancerNCT02768337Cambridge University Hospitals NHS Foundation Trust26
Unknown
2 期
Erlotinib With Concurrent Brain Radiotherapy and Secondary Brain Radiotherapy After Recurrence With Erlotinib in NSCLC Non-increased-intracranial-pressure Symptomatic Brain MetastasesNon-small-cell Lung CancerBrain MetastasesNCT01763385Wu Jieping Medical Foundation210